Multicenter trial of naloxone in Alzheimer's disease.
In a double-blind, placebo-controlled, crossover study of intravenously administered naloxone hydrochloride, 54 subjects with clinically ascertained Alzheimer's disease tested at three university centers showed no significant improvement in neuropsychological performance after 1-mg or 10-mg doses; 15 patients at 1 center were similarly unimproved after receiving 30 mg naloxone (single blind). Findings fail to support claims that naloxone monotherapy ameliorates cognitive impairments of Alzheimer's disease.
Henderson
V W
VW
Department of Neurology, University of Southern California School of Medicine, Los Angeles 90033.
Roberts
E
E
Wimer
C
C
Bardolph
E L
EL
Chui
H C
HC
Damasio
A R
AR
Eslinger
P J
PJ
Folstein
M F
MF
Schneider
L S
LS
Teng
E L
EL
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000523:psychology; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009270:Naloxone / Q000627:therapeutic use*; D009483:Neuropsychological Tests
D009270:Naloxone